Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06612788 · ClinicalTrials.gov registry record · NA
Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD)
A NA study, sponsored by West Virginia University.
- Completed
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT06612788 is a NA study that has completed, run by West Virginia University. The registered enrollment target is 5 participants.
The verdict
NCT06612788, a NA study, has completed, sponsored by West Virginia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to investigate Low Intensity Focused Ultrasound (LIFU) using the Exablate® Model 4000 Type 2.0/2.1 as an adjunctive neuromodulatory treatment for OUD (Opioid Use Disorder) by assessing its safety and tolerability in subjects with OUD.
Interventions
- DEVICE Exablate Model 4000 Type 2.0/2.1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-09-19 |
| Est. Completion | 2025-04-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06612788
The ClinicalTrials.gov registry entry for NCT06612788 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is West Virginia University, which has 122 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Exablate Model 4000 Type 2.0/2.1 is the first listed.
NCT06612788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06612788 about?
NCT06612788 is a clinical study titled "Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD)". The purpose of this clinical trial is to investigate Low Intensity Focused Ultrasound (LIFU) using the Exablate® Model 4000 Type 2.0/2.1 as an adjunctive neuromodulatory treatment for OUD (Opioid Use Disorder) by assessing its safety and tolerability in subjects with OUD.
What is the current status of trial NCT06612788?
This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2023-09-19. Estimated completion is 2025-04-25.
What interventions are being tested in trial NCT06612788?
The interventions under investigation include: Exablate Model 4000 Type 2.0/2.1 (DEVICE).
Who is sponsoring clinical trial NCT06612788?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.